



**DUNCAN MACKIE**  
**DIRECTOR OF PHARMACOLOGY AND**  
**EXPERIMENTAL THERAPEUTICS**  
**BUD & MARY'S**

**Join fellow faculty and trainees for our Seminar Series in Innovation & Entrepreneurship**

**This series was developed to foster entrepreneurial thinking in our research programs, clinical environments, educational endeavors, and service components.**

# **Innovation & Entrepreneurship Seminar Series**

**Sponsored by the SSPPS Director of Innovation & Commercialization**

**When: Feb. 21, 2025 1:30-2:30pm, MT**

**Where: SSPPS Building, Room 4000 (V20-4000)**

Our Seminar Series speaker will be Duncan Mackie, Director of Pharmacology and Experimental Therapeutics for Bud & Mary's where he applies his experience in drug discovery, cellular and molecular biology, and pharmacology. Dr. Mackie's R&D team is using neuronal and organoid 2D and 3D cellular cultures to investigate the effect of cannabinoids on the hallmarks of neuroinflammation.

He has developed a rigorous research program centered around the endocannabinoid system and its role in modulating the immune system during the onset of neurodegenerative diseases such as Alzheimer's and Parkinson's. Bud and Mary's was the first cannabis company to implement Current Good Manufacturing Practices, Good Agricultural and Collection Practices, and ISO17025 standards.

Prior to Bud & Mary's, Dr. Mackie conducted his doctoral studies at the University of Iowa's Department of Pharmaceutical Sciences and Experimental Therapeutics where he produced two provisional patents for his discoveries. Dr. Mackie conducted his post-doctoral research in the Department of Cellular Biology and Physiology at UNC-Chapel Hill.



**Skaggs School of Pharmacy and Pharmaceutical Sciences**

UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS